Kostas Biliouris
Stock Analyst at Oppenheimer
(1.09)
# 3,873
Out of 5,241 analysts
68
Total ratings
34.55%
Success rate
-17.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DSGN Design Therapeutics | Maintains: Outperform | $18 → $21 | $10.70 | +96.26% | 1 | May 4, 2026 | |
| SRPT Sarepta Therapeutics | Reiterates: Outperform | $37 | $17.01 | +117.52% | 10 | Mar 19, 2026 | |
| PRME Prime Medicine | Initiates: Outperform | $11 | $2.81 | +291.46% | 2 | Mar 12, 2026 | |
| PEPG PepGen | Initiates: Outperform | $15 | $1.47 | +920.41% | 1 | Feb 25, 2026 | |
| KRRO Korro Bio | Upgrades: Outperform | $22 | $9.97 | +120.66% | 4 | Jan 28, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $40 → $62 | $39.64 | +56.41% | 7 | Dec 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $286.27 | +64.18% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $72.52 | -3.47% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $0.8065 | +395.97% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.07 | +160.59% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $72 | $12.95 | +455.98% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $16.54 | +202.30% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $25 | $6.23 | +301.28% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $50 | $12.69 | +294.01% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $6.96 | +388.51% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.27 | +1,238.58% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $8.37 | +378.18% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $26.98 | +233.58% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $26.81 | +112.61% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $65.32 | -43.36% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $49.67 | +101.33% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $48.56 | +101.81% | 1 | Jun 17, 2022 |
Design Therapeutics
May 4, 2026
Maintains: Outperform
Price Target: $18 → $21
Current: $10.70
Upside: +96.26%
Sarepta Therapeutics
Mar 19, 2026
Reiterates: Outperform
Price Target: $37
Current: $17.01
Upside: +117.52%
Prime Medicine
Mar 12, 2026
Initiates: Outperform
Price Target: $11
Current: $2.81
Upside: +291.46%
PepGen
Feb 25, 2026
Initiates: Outperform
Price Target: $15
Current: $1.47
Upside: +920.41%
Korro Bio
Jan 28, 2026
Upgrades: Outperform
Price Target: $22
Current: $9.97
Upside: +120.66%
Centessa Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $40 → $62
Current: $39.64
Upside: +56.41%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $286.27
Upside: +64.18%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $72.52
Upside: -3.47%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $0.8065
Upside: +395.97%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.07
Upside: +160.59%
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $12.95
Upside: +455.98%
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $16.54
Upside: +202.30%
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $6.23
Upside: +301.28%
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $12.69
Upside: +294.01%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $6.96
Upside: +388.51%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.27
Upside: +1,238.58%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $8.37
Upside: +378.18%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $26.98
Upside: +233.58%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $26.81
Upside: +112.61%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $65.32
Upside: -43.36%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $49.67
Upside: +101.33%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $48.56
Upside: +101.81%